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Abstract
Platinum-based chemotherapy is not standard of care for unselected or genetically
selected metastatic castration-resistant prostate cancer (mCRPC) patients. A retro-
spective assessment of 71 patients was performed on platinum use in the
Netherlands. Genetically unselected patients yielded low response rates. For a
predefined subanalysis of all patients with comprehensive next-generation sequenc-
ing, 30 patients were grouped based on the presence of pathogenic aberrations in
genes associated with DNA damage repair (DDR) or aggressive variant prostate can-
cer (AVPC). Fourteen patients (47%) were DDR deficient (DDRd), of which seven
with inactivated BRCA2 (BRCA2mut). Six patients classified as AVPC. DDRd patients
showed beneficial biochemical response to carboplatin, largely driven by all
BRCA2mut patients having >50% prostate-specific antigen (PSA) decline and objec-
tive radiographic response. In the wild-type BRCA2 subgroup, 35% had a >50% PSA
decline (P = .006) and 16% radiographic response (P < .001). Median overall survival
was 21 months for BRCA2mut patients vs 7 months (P = .041) for those with func-
tional BRCA2. AVPC patients demonstrated comparable responses to non-AVPC,
including a similar overall survival, despite the poor prognosis for this subgroup. In
the scope of the registration of poly-(ADP)-ribose polymerase inhibitors (PARPi) for
mCRPC, we provide initial insights on cross-resistance between PARPi and platinum
compounds. By combining the literature and our study, we identified 18 patients
who received both agents. In this cohort, only BRCA2mut patients treated with
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platinum first (n = 4), responded to both agents. We confirm that BRCA2 inactivation
is associated with meaningful responses to carboplatin, suggesting a role for both
PARPi and platinum-based chemotherapy in preselected mCRPC patients.
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1 | BACKGROUND
Treatment options for metastatic castration-resistant prostate cancer
(mCRPC) have expanded over the past decades, but long-term overall
survival remains limited, with only a minority of patients surviving lon-
ger than 3 years after the development of castration resistance.1
Taxane chemotherapy (docetaxel and more recently cabazitaxel) has
shown considerable survival benefit, thus became part of the standard
care in patients with mCRPC alongside the next-generation hormonal
agents abiraterone and enzalutamide. Unfortunately, therapy resis-
tance inevitably occurs, and novel therapeutic regimens are heavily
sought after. After the results from the Phase III PROfound trial, the
first poly-(ADP)-ribose polymerase (PARP) inhibitor has recently
received FDA approval to be introduced for mCRPC patients
harbouring pathogenic defects in DNA damage repair genes [DDR
deficient (DDRd)].2 DDRd is present in up to 20% to 30% of the
mCRPC patients.3 These aberrations are common in genes (in)directly
involved in the homologous recombination pathway, such as BRCA1/2,
ATM and CHEK2 (amongst others). Inherited or somatic mutations in
these genes involved in the detection and repair of DNA strand
breaks lead to genomic instability, commonly resulting in a more
aggressive disease and worse clinical outcomes after treatment with
next-generation hormonal agents or taxanes.3 In this DDRd popula-
tion, clinical trials are investigating whether platinum compounds
may also be effective (NCT03652493, NCT02985021, NCT04038502,
NCT02598895, NCT03442556).
Platinum compounds in mCRPC have been evaluated in clinical
trials over the last three decades. A recent systematic review and
meta-analysis illustrated the use of platinum-based chemotherapy,
commonly in combination with taxanes.4 Results from a limited num-
ber of randomised controlled trials with platinum compounds, with
unselected patients, have shown no overall survival benefit when
compared to standard of care chemotherapies.5-7 Therefore,
platinum-containing regimens are not current standard of care for
molecularly unselected patients with mCRPC. In patients with DDRd
tumours, multiple retrospective studies and case series have shown
clinical meaningful responses to platinum compounds.8-10 A recent
study demonstrated biochemical responses in half of the patients
with DDRd, particularly those with BRCA2 aberrations, as well as
those with alterations in PALB2, FANCA or CDK12.11 Patients with
small cell (neuroendocrine) prostate cancer (SC-NEPC) appear to
show superior disease control with platinum-based regimens over
standard of care taxane chemotherapy for mCRPC.12,13 A recent
study identified patients with aggressive variant prostate cancer
(AVPC), as a subtype defined as either SC-NEPC or prostate adeno-
carcinoma with clinicopathological features associated with poor
outcome, to benefit most from platinum-based regimens.14 This sub-
type is molecularly characterised by combined alterations in RB1,
TP53, and/or PTEN.15 The beneficial responses of distinct subtypes
underscore that platinum-based chemotherapy may have a role in
postponing progression and improving quality of life in selected
patient groups.
In this report, we assessed real-world use, and outcomes from
platinum-based chemotherapy in the Netherlands. Next, we exam-
ined the association between DDR alterations and platinum sensitiv-
ity in a retrospective study cohort with comprehensive tumour
and/or germline sequencing data available. We describe responsive-
ness of patients with germline and/or somatic alterations in a range
of DDR genes, focusing on alterations in BRCA2, molecular features
of AVPC and exceptional responders. Lastly, in the wake of registra-
tion of multiple PARP inhibitors (PARPi) for mCRPC, it is important
to investigate whether antitumour efficacy remains to PARPi after
exposure and resistance to platinum, and vice versa. We provide
new data on this cross-resistance between platinum chemotherapy
and PARPi.
What's new?
Platinum-based chemotherapy is not standard of care for
unselected or genetically-selected patients with metastatic
castration-resistant prostate cancer (mCRPC). However, sev-
eral studies have shown that platinum-based chemotherapy
may still have a role in postponing progression in selected
patient groups. This new study investigating DNA damage
repair gene alterations and response to platinum-based che-
motherapy provides evidence that deep and durable
responses are primarily associated with patients harbouring
BRCA2 inactivation. Based on these data and the limited
available literature, platinum-based chemotherapy followed
by PARP inhibition is potentially emerging as the optimal
treatment sequence in pre-selected mCRPC patients.
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2 | METHODS
2.1 | Patient population and study design
The main study population of this retrospective cohort study con-
sists of all mCRPC patients who started with platinum-based chemo-
therapy in the Radboudumc between July 2014 and January 1, 2020
(n = 36). The primary objective was to evaluate platinum responsive-
ness in patients with diverse alterations in genes directly or indirectly
involved in DDR. All 30 patients were included that had undergone
comprehensive genetic analysis by targeted or whole-genome
sequencing of primary or metastatic tumour tissue. For the compari-
son of outcome from platinum-based chemotherapy, between a ter-
tiary referral centre cohort (Radboudumc) and a real-world CRPC
cohort, 36 patients in the Castration-Resistant Prostate Cancer Regis-
try (CAPRI) were identified. One patient was present in both cohorts.
CAPRI is a population-based, observational, retrospective registry
based on pseudonymised patient files from CRPC patients from
20 hospitals in the Netherlands, balanced geographically and by type
of hospital.1 Identified patients from CAPRI received platinum-based
chemotherapy somewhere between January 2010 and December
2017, with follow-up until January 2019. CAPRI is registered in the
Dutch Trial Registry as NTR3591.
Demographic, clinical and histopathological data as well as diag-
nostic parameters were extracted from the electronic patient records.
In the Radboudumc cohort, a structured analysis was performed
based on the presence of at least one (likely) pathogenic somatic
and/or germline aberration in BRCA2 (BRCA2mut) as well as a
predefined panel of genes directly or indirectly involved in DDR
(DDRd), and a DDR proficient group (DDRp). All data were stored
anonymously. Patient follow-up for the Radboudumc was until the
May 01, 2020, lost-to-follow-up or death.
The Dutch cohort of patients from CAPRI was compared to the
Radboudumc cohort. An AVPC population was identified within the
Radboudumc cohort based on a molecular signature (AVPC-MS).
Cases with exceptional responses, defined as a prostate-specific anti-
gen (PSA) decline of more than 90% after platinum-based chemother-
apy, were analysed more comprehensively with additional tests. In
addition, patients who received both PARPi and platinum compounds
were identified for exploratory analysis and included until June 2020.
2.2 | Genetic testing
Archived or fresh tumour material was sequenced by either a non-
profit service provider (Center for Personalized Cancer Treatment
[CPCT]), or fee for service provider (Foundation Medicine [FMI]) and
often additionally sequenced by a custom in-house NGS platform.16,17
The Pathogenicity of the alterations was analysed (Peter H. J.
Slootbeek) and reassessed in a blinded manner by an experienced clin-
ical molecular biologist (Leonie I. Kroeze) at the Department of Pathol-
ogy, according to the guidelines for sequence variants.18 Gene
disruptions were classified as variant of unknown significance (VUS).
The predefined genes of interest for the DDRd group consisted of:
ATM, ATR, BAP1, BARD1, BRCA1, BRCA2, BARD1, BRIP1, CDH1,
CDK12, CHEK1, CHEK2, ERCC2, ERCC4, FANCA, FANCC, FANCD2,
FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, MRE11A, NBN,
PALB2, PARP1, PARP2, PARP3, PPP2R2A, RAD51, RAD51B, RAD51C,
RAD51D, RAD52, RAD54L and RPA1. To meet the AVPC-MS, deleteri-
ous aberrations in at least two of TP53, RB1 or PTEN needed to be
present in the biopsied tumour material.15 The DNA mismatch repair
(MMR) genes MSH2, MSH6, MLH1 and PMS2, not in the predefined
DDRd list, were nevertheless included in the results, to give full
insight on the DDRd genomic profile of the study subjects, even
though MMR deficiency alone is not associated with response to plat-
inum or PARPi.
2.3 | Study outcomes
Biochemical (PSA) response to platinum-based chemotherapy was the
primary outcome of this study. Patients with baseline PSA values
below 2 μg/L were excluded for biochemical analyses. PSA responses
were assessed according to the Prostate Cancer Clinical Trials Work-
ing Group criteria,19 with assessment of declines of >50% (PSA50) and
>90% (PSA90). If PSA declined at any time from initiation of platinum-
based therapy until next therapy, this value was used to calculate
maximal change. If possible, early PSA rises before 12 weeks of ther-
apy were ignored. Patients with early biochemical, radiological or clini-
cal progression, and therefore a missing 12-week PSA, were defined
as PSA50 nonresponders in the analyses of PSA change at 12 (±2)
weeks. Secondary outcomes were overall survival (OS) and best radio-
graphic response. OS was defined as time from initiation of platinum-
based chemotherapy trough date of death from any cause or censored
at last date of follow-up if alive. Best radiographic response was clas-
sified according to Response Evaluation Criteria in Solid Tumours
(RECIST 1.1) criteria.20
2.4 | Statistical analyses
Baseline characteristics and biochemical outcomes between the sub-
groups were compared using the Pearson chi-square or Fisher exact
test for categorical variables and the nonparametric Mann-Whitney
U test for continuous variables. Kaplan-Meier curves were used to
visualise the survival and if adequate, OS was compared using
univariable Cox proportional hazards models. A two-sided P value
<.05 was considered significant. Factors associated with response
were identified using a univariable and multivariable linear regression.
To adhere to the presumptions of the regression model, the maximal
PSA change underwent additive and square root transformation. Vari-
ables with a P value <.20 in the univariable analyses were included for
a multivariable linear regression analysis. The multivariable model was
fitted by including variables in the model with a forward selection
strategy with an entry level of 0.05 at every step. Statistical tests
were performed using SPSS software (v25).
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3 | RESULTS
3.1 | Baseline characteristics and efficacy
of platinum chemotherapy in the CAPRI and
Radboudumc cohorts
In the Dutch population-based CAPRI, 36 patients were treated with
platinum-based chemotherapy in a time frame of 8 years. No data
were available on their molecular underpinnings. From the
Radboudumc, the same number of patients (36) was included. One
patient treated in the Radboudumc was also registered in CAPRI. The
CAPRI and the Radboudumc cohort were considered unmatched
populations (Table S1). Baseline alkaline phosphatase (ALP) and PSA
were higher in the Radboudumc cohort when compared to the CAPRI
cohort (ALP: 234 vs 126 U/L; PSA: 105 vs 52 μg/L).
For the CAPRI cohort, the median age at start of platinum-based
chemotherapy was 70 years. Patients were treated with cisplatin in
19% of the cases and with carboplatin in 81%, two patients received
the latter as monotherapy. The most frequent combination partners in
the remaining cases were docetaxel (33%) and etoposide (33%)
(Table S2). The proportion of patients with a PSA50 response was
16.7% in this cohort (Table S3). Median OS from start of platinum-
based chemotherapy was 7.0 months (Figure S1).
The median age of the Radboudumc cohort was 62 years at initia-
tion of platinum-based chemotherapy. All patients were treated with
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F IGURE 1 Treatments and mutational landscape of the Radboudumc cohort. A, Swimmerplot presenting the duration on platinum-based
chemotherapies and subsequent therapies until death or last follow-up. The colour scheme represents all therapies and the symbols indicate best
radiographic response or status at last follow-up. B, Swimmerplot starting at date of mCRPC and visualising only the period on treatment for each
therapy given. The symbol indicates the administration of upfront docetaxel in hormone sensitive setting. Study subject 30 received a trial with
docetaxel and an inhibitor of cytotoxic T-lymphocyte-associated Antigen 4 in hormone sensitive setting. C, Oncoplot showing the pathogenic or
likely pathogenic alterations of the Radboudumc cohort in predefined genes directly or indirectly involved with DNA damage repair (DDR), genes
in the aggressive-variant prostate cancer molecular signature (AVPC-MS), and mismatch repair (MMR) genes. The colour of the boxes represent
the effect of the mutation. Split boxes indicate two different alterations in the same gene. Germline mutations are accentuated. The AVPC bar
identifies patients meeting the AVPC-MS criteria and PSA50 identifies patients having a >50% PSA decline to carboplatin. CNV, copy number
variant; PD, progressive disease; PR, partial response; SD, stable disease [Color figure can be viewed at wileyonlinelibrary.com]
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as monotherapy. PSA50 response was observed in 47.1% of the
patients from the Radboudumc cohort. OS was comparable to the
CAPRI cohort with a median of 7.3 months.
3.2 | Molecular landscape of patients included
in the Radboudumc cohort
Of the 36 patients in the Radboudumc cohort, 30 underwent compre-
hensive genetic analysis. All therapies since diagnosis of castration-
resistance for the molecularly profiled patients are depicted in
Figure 1. In general, patients were heavily pretreated and received a
median of three lines of systemic therapies between castration-
resistance and initiation of platinum-based therapy. All but two
(Subjects 12 and 25) underwent prior treatment with a taxane. Four-
teen of the 30 evaluable patients (47%) harboured deleterious genetic
alterations in the predefined genes directly or indirectly involved in
DDR (DDRd), half of these patients had a (likely) pathogenic BRCA2
alteration (BRCA2mut) (Figure 1C). Other pathogenic alterations were
identified in BRCA1 (n = 1), ATM (n = 3), ATR (n = 1), CDK12 (n = 2),
CHEK2 (n = 2), FANCD2 (n = 1). The remaining 16 patients (53%) were
genetically DDRp, of which in five patients a VUS was detected in
one of the predefined DDR genes (Table S4). Six patients (20%)
showed a molecular signature of AVPC (AVPC-MS) with inactivation
of ≥2 associated genes (TP53, RB1, PTEN), of which subject 16 was
also BRCA2 deficient. Two patients (7%) showed inactivation of one or
more MMR genes and one of them was also DDRd. Microsatellite
instability was detected in both patients. Out of the 48 alterations
depicted in Figure 1C, 35 (73%) were proven to be somatic. Three
mutations in BRCA2 and one in CHEK2 were germline. For the
remaining nine alterations the germline status was not assessed
(Table S4). Study subject 18 had a loss of one allele of BRCA2 and the
zygosity of the BRCA2 loss of study subject 33 was unknown. All other
copy number variants were homozygous deletions.
3.3 | Efficacy of carboplatin-based chemotherapy
in molecular subtypes of mCRPC
3.3.1 | Baseline comparison DDRd vs DDRp
subgroups
At baseline, clinical characteristics and demographics did not differ sig-
nificantly between the DDRd and DDRp subgroups (Table S5). Median
PSA and ALP at start of therapy were higher in the DDRd subgroup
when compared to DDRp patients (PSA: 300 vs 100 μg/L, P = .031;
ALP 278 vs 146 U/L, P = .036, respectively). In both subgroups,
cabazitaxel was the preferred combination partner of platinum
(Table S2). For the BRCA2mut subgroup, the median time from initial
diagnosis to initiation of platinum-based therapy was 30 months, when
compared to 56 months for the BRCA2 wild-type (BRCA2wt) subgroup
(P = .037). At baseline, these subgroups were not statistically different.
3.3.2 | Outcome
Of the DDRd patients, 10 (71%) had a PSA50 response when com-
pared to 5 (31%) in the DDRp subgroup (P = .028, Figure 2). All other
PSA outcome metrics also demonstrated a more beneficial response
to carboplatin for the DDRd subgroup (Table 1). Best radiographic
response according to RECIST 1.1 criteria (Table 2) and OS did not
statistically differ between the DDRd and DDRp subgroups (OS 8.4 vs
7.0 months, respectively; hazard ratio [HR] 1.720; 95% confidence
interval [CI] 0.732-4.043; P = .214, Figure 3).
Next, we focussed on the BRCA2 status of the 30 molecularly pro-
filed patients and compared the seven BRCA2mut patients to the
23 BRCA2wt patients. All outcome measures significantly favoured the
BRCA2mut subgroup (Table 1). All patients in the BRCA2mut subgroup
witnessed a PSA50 response, while this was 35% in the BRCA2wt sub-
group, P = .006. Moreover, all seven BRCA2mut patients showed a
radiographic partial response when compared to 16% in the BRCA2wt
subgroup (P < .001, Table 2). Median OS from start of carboplatin was
almost 14 months longer for the BRCA2mut subgroup when com-
pared to the BRCA2wt subgroup (21.1 vs 7.3 months; HR 3.588; 95%
CI 1.051-12.248; P = .041, Figure 3). In a multivariable analyses
BRCA2 status emerged as the independent predictor for PSA response
(Table S6).
Of the 15 patients in the Radboudumc cohort with a PSA50, 27%
(n = 4) were defined as exceptional responders, with a PSA90
response. All harboured at least one pathogenic BRCA2 aberration.
Their median radiographic progression-free survival was 6 months
(range 3-10 months). Subject 18 did not classify as BRCA2mut based
on the routine next-generation sequencing, but a loss of heterozygos-
ity of BRCA2 was implied. An additional genetic analyses with multi-

































































































F IGURE 2 Waterfallplot of the best PSA change to carboplatin.
Colour indicates whether a study subject is in the DDRd or DDRp
subgroup. BRCA2mut and AVPC patients are marked accordingly.
AVPC, aggressive-variant prostate cancer; DDRd, DNA damage repair
deficient; DDRp, DNA damage repair proficient; PSA, prostate-
specific antigen [Color figure can be viewed at wileyonlinelibrary.com]
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F IGURE 3 Kaplan–Meier curves visualising overall survival (OS) for DDRp vs DDRd (left) and BRCA2wt vs BRCA2mut (right). BRCA2mut,
inactivated BRCA2; BRCA2wt, BRCA2 wild-type subgroup; DDRd, DNA damage repair deficient; DDRp, DNA damage repair proficient [Color
figure can be viewed at wileyonlinelibrary.com]
TABLE 1 PSA response to carboplatin, by DDR and BRCA2 status
Number of patients (valid %) or
median [IQR]
Number of patients (valid %) or
median [IQR]




N = 23 P value
Maximal PSA change (%) −70 [−99 to +13] 8 [−53 to +133] .013 −99 [−99 to −85] 7 [−66 to +103] <.001
Patients with >50% maximal PSA decline 10 (71.4) 5 (31.3) .028 7 (100.0) 8 (34.8) .006
Patients with >90% maximal PSA decline 4 (28.6) 0 (0.0) .037 4 (57.1) 0 (0.0) .001
PSA change at 12 weeks (%) −66 [−97 to −14] 0 [−61 to +186] .021 −96 [−99 to −62] 0 [−65 to +131] .002
Patients with >50% PSA decline at
12 weeks
10 (71.4) 3 (21.4) .008 7 (100.0) 6 (28.6) .001
Abbreviations: BRCA2mut, inactivated BRCA2; BRCA2wt, BRCA2 wild-type subgroup; DDR, DNA damage repair; DDRd, DDR deficient; DDRp, DDR profi-
cient; IQR, interquartile range; PSA, prostate-specific antigen. Values in bold are significant (P < .05).
TABLE 2 Best radiographic response
to carboplatin, by DDR, BRCA2 and
AVPC status
Subgroups Best radiographic responsea Number of patients (valid %) P value
DDRd vs DDRp Partial response 7 (58.3) vs 3 (21.4) .122
Stable disease 2 (16.7) vs 2 (14.3)
Progressive disease 3 (25.0) vs 9 (64.3)
BRCA2mut vs BRCA2wt Partial response 7 (100.0) vs 3 (15.8) <.001
Stable disease - vs 4 (21.1)
Progressive disease - vs 12 (63.2)
AVPC vs non-AVPC Partial response 3 (50.0) vs 7 (35.0) .690
Stable disease - vs 4 (20.0)
Progressive disease 3 (50.0) vs 9 (45.0)
Abbreviations: AVPC, aggressive-variant prostate cancer; BRCA2mut, inactivated BRCA2; BRCA2wt,
BRCA2 wild-type subgroup; DDR, DNA damage repair; DDRd, DDR deficient; DDRp, DDR proficient.
Values in bold are significant (P < .05).
According to Response Evaluation Criteria in Solid Tumours (RECIST1.1).
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3.3.3 | Aggressive variant prostate cancer
We identified six AVPC patients, defined by molecular signatures,
with inactivation of TP53, RB1 and PTEN (n = 1), TP53 and RB1 (n = 2),
TP53 and PTEN (n = 2) and PTEN and RB1 (n = 1). These six AVPC
patients were of younger age compared to the 24 patients in the non-
AVPC subgroup (median 57 vs 63 years, P = .029). Other baseline
characteristics were comparable (Table S7). The duration of platinum-
based treatment did not differ significantly (Table S8).
PSA responses to carboplatin-based chemotherapy were compa-
rable between the AVPC and the non-AVPC subgroup (Table S9). In
both groups, half of the patients had a PSA50 response to treatment
with carboplatin. The AVPC subgroup showed a 1.8-month numerical
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F IGURE 4 A, Swimmerplot showing a
sub cohort of patients who received both
platinum compounds and PARP inhibitors.
The colour scheme represents therapies. B,
Individual patient plots visualising the PSA
kinetics starting from first targeted therapy
till discontinuation of sequential therapy,
for patients who received both platinum
compound and PARP inhibitors (PARPi).
Above each plot, the subject ID and
mutation for enrolment to PARPi are
indicated. The line is coloured coded based
on treatment and the symbols indicate best
radiographic response or further disease
course. The PSA of study subject 01 starts
at 640 ng/L. Note: Not all y-axes extend to
zero. PARP, poly-(ADP)-ribose polymerase;
PD, progressive disease; PR, partial
response; PSA, prostate-specific antigen;
SD, stable disease [Color figure can be
viewed at wileyonlinelibrary.com]
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respectively; Figure S1). Best radiographic response was comparable
between both subgroups (Table 2). These comparable responses to
carboplatin-based chemotherapy are in contrast with the tendency of
AVPC patients to show worse outcome metrics to standard of care
therapy, and a poorer survival compared to non-AVPC patients.
3.4 | Responses in patients with both PARP
inhibitors and platinum-based therapy
In the scope of registration of PARPi for mCRPC, it is key to have
insight in possible cross-resistance between platinum compounds and
PARPi. Here, we evaluated response rates to carboplatin and PARPi in
a small subcohort; nine patients from the Radboudumc cohort were
treated with PARPi during the course of their disease, all subsequent or
prior to treatment with carboplatin (Figure 4A). Subject 27 was
excluded from the analyses due to a lack of adequate follow-up after
PARPi. The remaining eight patients harboured alterations in BRCA2
(n = 4), ATM (n = 2), PPP2R2A (n = 1, not in predefined DDR panel) and
CDK12 (n = 1). Subject 16 harboured pathogenic alterations in BRCA2
as well as ATM. All four BRCA2mut patients with initial PSA50 response
to carboplatin, also showed a PSA50 response to subsequent PARPi
(Figure 4B). Moreover, every BRCA2mut patient had a radiographic
response to initial platinum therapy and three out of four also to subse-
quent PARPi therapy. Notably, study Subject 16 (BRCA2 loss and ATM
frame shift mutation) showed outstanding response to consecutively
carboplatin, PARPi and carboplatin rechallenge, with maximum PSA
decline of 99%, 83% and 82%, respectively. Radiographically, partial
response was observed following all three therapies in this patient.
We assessed the literature for additional patient data, and
extended the inclusion period for patients within our institute for an
exploratory analysis of cross-resistance between these compounds
(Table S10). In total, we could identify 18 patients, of which 2 patients
from our institute who received their first dose of platinum-based che-
motherapy after the inclusion period of our main study. PSA response
was missing for one patient and radiographic response for four. Eight
patients (47%) showed differential responses, showing either PSA50
responsiveness to platinum or PARPi, but not to the second agent.
There were five patients (29%) with concordance in nonresponsiveness
and four (24%) with concordance in responsiveness, of those all four
BRCA2mut patients treated with platinum first and subsequently with
PARPi. In the reverse sequence (PARPi followed by platinum-based
chemotherapy) none of the five patients with response to PARPi
responded to sequential platinum-based chemotherapy, while 43%
(3/7) of the patients without response to PARPi responded to platinum.
Only one of the four patients with an ATM mutation had a PSA50
response to PARPi and none had such response to platinum.
4 | DISCUSSION
We have described the real-world use and outcomes of treatment
with platinum compounds in mCRPC patients in the Netherlands.
A molecularly unselected patient population of the nationwide Dutch
CAPRI cohort yielded low response rates to platinum-based treat-
ment. The CAPRI and the Radboudumc cohort were considered
unmatched populations. It cannot be excluded that differences in
response to platinum-based chemotherapy might be influenced by
confounders like age at start of platinum-based therapy or the combi-
nation partner of the platinum agent. In the Radboudumc cohort, we
specifically investigated the response of patients with or without
DNA damage repair defects or a molecular signature of AVPC. These
results supported existing evidence on antitumour activity of platinum
combination therapy in patients with DDRd prostate cancer. More
than 70% of the patients in the DDRd subgroup demonstrated a bio-
chemical response to carboplatin. Half of the DDRd patients
harboured a pathogenic BRCA2 alteration, and particularly these
patients benefitted from carboplatin-based chemotherapy as shown
by higher objective radiographic response rates and longer OS on top
of a PSA50 response for all BRCA2mut patients. Despite their poor
prognosis, AVPC patients had comparable outcomes as non-AVPC
patients, suggesting a possible benefit of platinum-based chemo-
therapy.
DDRd, and particularly genes associated with homologous
recombination, are suggested as plausible biomarkers for platinum
responses in mCRPC.10 A recent study by Mota et al. described a
higher proportion of PSA50 responses to platinum-based chemother-
apy in the DDRd group when compared to DDRp patients.11 In our
study, a similar outcome was found, although the biochemical
response of DDRd patients to carboplatin was largely driven by the
BRCA2mut subgroup, with all seven BRCA2mut patients showing a
PSA50 response. In comparison, four out of six (67%) BRCA2mut
patients in the study of Mota et al. had a similar response. This excep-
tional responsiveness of BRCA2 inactivated patients to platinum-
based chemotherapy was previously described in a case series of
three patients by Cheng et al, supported by an in vitro and in vivo
study.8,9 We strongly underline these findings, with all BRCA2mut
patients in our study also demonstrating an objective radiological
response with clinical benefit suggested by a significant longer OS
witnessed in this subgroup.
Novel opportunities for patients with mCRPC have arisen due to
advances in molecular characterisation and personalised medicine.
One avenue is on targeting DDRd. Besides platinum compounds,
PARPi have shown very promising results in Phase 1 and 2 trials.21-23
Recently, these findings were validated in the Phase III PROfound
trial.2 Patients with BRCA2 alterations seemed to benefit most from
the inhibition and trapping of the PARP-1 and PARP-2 enzymes.
Through the inhibition of repair of single strand DNA breaks, PARPi
add to the formation of lethal double strand breaks, in the presence of
DDRd, leading to apoptosis and programmed cell death. The potential
benefit of the combination of PARPi and platinum compounds over
PARPi alone appears encouraging; however, this is not yet investi-
gated in mCRPC.24
At this moment, the question remains how-to best sequence plat-
inum compounds with PARPi in DDRd patients with mCRPC. Particu-
larly, after registration of PARP inhibitors, it is expected that PARPi
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will be favoured over platinum compounds. Issues of cross-resistance
need to be adequately addressed. We evaluated responses to these
therapies in patients from our institute and from Mota et al.11 Only
four patients had a PSA50 response to both therapies, all BRCA2
mutated and treated with platinum first and subsequently PARPi. In
the reverse sequence (PARPi – platinum), all patients who responded
to PARPi did not respond to platinum compounds, but almost half of
the nonresponders did remain responsive to platinum. Notably, ATM
mutated patients yielded low response to both PARPi and platinum-
based chemotherapy. This is in line with early data suggesting that
response to platinum and PARPi is more commonly seen in BRCA2
mutated patients when compared to ATM mutated patients.25 Our
combined sample size of 18 patients was relatively small and insuffi-
cient to draw conclusions on the order of applying these two types of
therapy. More data are needed, preferably from randomised trials
with platinum-based chemotherapy vs PARPi with crossover design,
to provide recommendations on optimal treatment planning on a
DDRd gene-specific basis.
In end-stage castration-resistant disease, patients commonly
develop poor prognostic disease features associated with AVPC, for
which effective therapy is much sought after. Recently, Corn et al
have shown that multimodality chemotherapy of carboplatin in combi-
nation with cabazitaxel, improved radiographic progression-free sur-
vival, but not OS, over cabazitaxel alone in a molecularly unselected
patient cohort.14 Post hoc analyses suggested that AVPC-MS-positive
patients derived most benefit from the combination, indicated by both
radiographic progression-free survival (2.2 vs 6.0 months, P < .05) and
OS benefit (9.9 vs 17.4 months, P < .05). Our results were in line with
this study, demonstrating comparable OS and PSA responses for
AVPC and non-AVPC patients treated with carboplatin. In contrast to
our study, no clear benefit for BRCA2-deficient patients was found in
the study by Corn et al, possibly due to challenges and difficulties in
utilising ctDNA for the detection of the full spectrum of BRCA2 alter-
ations, particularly deletions.
AVPC and DDRd patients may both benefit from platinum-based
chemotherapy trough a similar method of action. TP53 and PTEN are
part of the AVPC-MS. P53 is a mediator of DDR, since it promotes
cell cycle arrest and provides time for the DDR machinery to repair
the damage, or induces senescence/cell death in response to DNA
damage.26,27 Although not yet confirmed in a clinical setting, PTEN
alterations in an in vitro setting appear to influence homologous
repair, in such a way that PTEN-deficient prostate cancer cells are sus-
ceptible to treatment with PARPi.28,29 Moreover, a preclinical study
demonstrated in vitro and in vivo, that a senescence response to
PARPi triggered by PTEN deficiency in prostate cancer cells, trans-
formed to apoptosis in case of additional p53 dysfunction.30 These
two molecular subtypes may both have an increased vulnerability to
the DNA crosslinking and strand breakage of platinum compounds
through the accumulation of cell damage caused by the inability to
correctly restore the DNA sequence.
Recently, SLFN11 expression has also been suggested as a
predictive biomarker for response to DNA-damaging agents. This
DNA/RNA helicase, overexpressed in approximately 45% of the
mCRPC tumours, was associated with a longer progression-free sur-
vival in CRPC patients upon treatment with platinum-based chemo-
therapy in a recent study by Conteduca et al..31 In a multivariable
analysis it emerged as an independent predictor for a longer
progression-free survival; no detailed breakdown on gene level was
given of the 17 patients with DDRd, therefore it is hard to interpret
whether SLFN11 may outperform BRCA2. Homologous recombina-
tion deficiency signatures may also outperform BRCA2 as predictive
biomarker, as BRCA1/2 may be silenced by methylation or posttrans-
lational processes. Approximately 30% of mCRPC patients with a
homologous recombination deficiency signature lacked alterations in
BRCA2 and other key homologous recombination genes.32 Also, the
neutrophil to lymphocyte ratio, a well-known prognostic factor in
mCRPC was shown to be independently associated with worse out-
comes after platinum therapy.33
Our results should be viewed in the context of several limitations.
The retrospective nature of this study allows for selection bias. No
prior power analysis was performed, and the sample size is based on
consecutively enrolling patients treated with platinum-based chemo-
therapy. The size of the cohort and lack of randomisation allow base-
line imbalances such as higher PSA and ALP levels for DDRd patients,
which might influence the response measures. Genetic analysis was
performed by three different next generation sequencing platforms.
We tried to mitigate differences in pathogenicity reporting, by
reassessing the pathogenicity from third-party providers, which was
performed in a blinded manner by an experienced clinical molecular
biologist. Due to the nature of our retrospective study, which lacked a
comparator arm without use of platinum chemotherapy, the specified
OS results and intergroup comparison were in the context of DDRd
gene-specific prognosis.
5 | CONCLUSIONS
Our study adds to a body of evidence that platinum compounds are
beneficial for mCRPC patients pre-selected for BRCA2 alterations.
These data are of importance to help protect patients from unneces-
sary toxicity and adverse events, with platinum-based drugs commonly
administered as a last resort therapy. The individual benefit of infre-
quent alterations in DNA damage repair genes, including PALB2, BRIP1
and others, to platinum chemotherapy is unknown. Carboplatin, when
given prior to PARPi, did not appear to diminish efficacy to subsequent
PARPi, however more data is required to gain insight on cross-resis-
tance. AVPC patients also seemed to benefit from platinum compounds
indicated by comparable responses for this prognostic poor subgroup.
This study provides novel data which may help guide the path towards
improved precision medicine for patients with mCRPC.
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